Nexmed - Best Pharma Stocks of 2007

Company: Nexmed
Starting stock price: $0.72
Ending stock price: $1.42
Percent Change: 97.22%

Details: Nexmed is using NexACT--it's transdermal drug delivery technology--to create therapies that can be delivered directly through the skin. The company is developing treatments for sexual disorders and nail fungus. In 2007 Nexmed completed patient enrollment in two Phase III studies for it's anti-fungal product, and filed an NDA for an erectile dysfunction treatment.

More News:
NexMed taps Berman as new CEO. Report

Nexmed - Best Pharma Stocks of 2007
Read more on

Suggested Articles

Companies considering this avenue must think through potential implications despite the obvious attraction of early access for patients.

BD says a $1.2 billion investment in its pre-filled syringe business will add surge capacity needed to meet demand in future pandemics.

Ad Environment Matters for Message Receptivity